Celularity Inc - ESG Rating & Company Profile powered by AI
This assessment of Celularity Inc incorporates data from across the internet and also from available documents by Celularity Inc. This SDG score for Celularity Inc indicates the company's transparency towards the United Nations SDGs. The page displays a zero-cost Sustainability analysis for Celularity Inc.
Celularity Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 5.3, social score of 8.0 and governance score of 8.0.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 217 | Takara Bio Inc | 7.2 | High |
| 217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
| 224 | Celularity Inc | 7.1 | High |
| 224 | Bilcare Ltd | 7.1 | High |
| 224 | Blueprint Medicines Corp | 7.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Celularity Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Celularity Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Celularity Inc report the average age of the workforce?
Sign up for free to unlockDoes Celularity Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Celularity Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Celularity Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Celularity Inc offer flexible work?
Sign up for free to unlockDoes Celularity Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Celularity Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Celularity Inc conduct supply chain audits?
Sign up for free to unlockDoes Celularity Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Celularity Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Celularity Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Celularity Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Celularity Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Celularity Inc disclose water use targets?
Sign up for free to unlockDoes Celularity Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Celularity Inc have a product recall in the last two years?
Sign up for free to unlockDoes Celularity Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Celularity Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Celularity Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Celularity Inc disclose parental leave metrics?
Sign up for free to unlockDoes Celularity Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Celularity Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Celularity Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Celularity Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Celularity Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Celularity Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Celularity Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Celularity Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Celularity Inc disclose its waste policy?
Sign up for free to unlockDoes Celularity Inc report according to TCFD requirements?
Sign up for free to unlockDoes Celularity Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Celularity Inc disclose energy use targets?
Sign up for free to unlockDoes Celularity Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Celularity Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Celularity Inc
These potential risks are based on the size, segment and geographies of the company.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.